ARDS (Aridis Pharmaceuticals) Asset Impairment Charge : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Asset Impairment Charge?

Aridis Pharmaceuticals's Asset Impairment Charge for the three months ended in Sep. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Aridis Pharmaceuticals Asset Impairment Charge Historical Data

The historical data trend for Aridis Pharmaceuticals's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Asset Impairment Charge Chart

Aridis Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Asset Impairment Charge

Get a 7-Day Free Trial

0.23

Aridis Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Aridis Pharmaceuticals Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aridis Pharmaceuticals Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Aridis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

983 University Avenue, Building B, Los Gatos, CA, USA, 95032

Website

https://www.aridispharma.com

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

Executives

Vu Truong	director, 10 percent owner, officer: CEO, CSO, Director	5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer	director, 10 percent owner	5941 OPTICAL CT., SAN JOSE CA 95138
Fibrosis Foundation Cystic	10 percent owner	4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri	officer: Chief Medical Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
John F Hamilton	director	1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak	officer: Chief Financial Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland	officer: Chief Financial Officer	C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo	director
Shawn Lu	director	C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin	director	5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025